Search results
Showing 121 to 135 of 1373 results for patients and public
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
In development [GID-TA11197] Expected publication date: TBC
In development [GID-TA11390] Expected publication date: 24 July 2024
This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.
View quality statements for QS88Show all sections
Sections for QS88
- Introduction
- List of quality statements
- Quality statement 1: Structured clinical assessment
- Quality statement 2: Psychological therapies – borderline personality disorder
- Quality statement 3: Psychological therapies – antisocial personality disorder
- Quality statement 4: Pharmacological interventions
- Quality statement 5: Managing transitions
- Quality statement 6: Education and employment goals
Resources to help organisations who want to help develop NICE guidance
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: TBC
In development [GID-TA11263] Expected publication date: TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
In development [GID-TA11249] Expected publication date: 17 July 2024
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]
In development [GID-HST10055] Expected publication date: 29 January 2025
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
In development [GID-TA10143] Expected publication date: TBC
In development [GID-TA11184] Expected publication date: TBC
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
In development [GID-TA10999] Expected publication date: 21 August 2024